Neomycin Sulphate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Skin Infection, Eye Infection, Ear Infection, Vaccine Production, Veterinary Medicine, Others), By Region and Competition, 2020-2030F

April 2025 | 185 pages | ID: N01BBFB279CCEN
TechSci Research

Abstracts

The Global Neomycin Sulphate Market was valued at USD 246.80 million in 2024 and is projected t%li%reach USD 382.05 million by 2030, growing at a CAGR of 5.22%. Neomycin sulphate, a broad-spectrum aminoglycoside antibiotic, is widely used t%li%treat bacterial infections in both humans and animals. Its effectiveness, affordability, and application in topical and oral formulations make it a preferred choice in managing infections such as skin conditions and gastrointestinal disorders. The market is expanding due t%li%rising incidences of bacterial infections and increased focus on preventive healthcare, especially in developing regions where limited access t%li%clean water and sanitation persists. Neomycin sulphate’s therapeutic versatility, combined with its cost-effectiveness, continues t%li%support its use across both pharmaceutical and veterinary domains.

Key Market Drivers

Growth in Healthcare Industry

The ongoing expansion of the global healthcare industry is significantly driving demand for neomycin sulphate. With global healthcare generating over USD 4 trillion annually, the pharmaceutical and biotechnology segments alone account for approximately USD 850 billion. Neomycin sulphate plays a critical role in treating infections of the skin, eyes, and intestines, and is frequently used in both over-the-counter and prescription drugs. The growing burden of infectious diseases, especially in developing economies with inadequate sanitation infrastructure, reinforces the need for effective antimicrobials. Healthcare institutions rely heavily on neomycin sulphate for its broad-spectrum antibacterial capabilities, particularly in outpatient and surgical environments. As healthcare access improves globally, s%li%does the reliance on reliable antibiotics like neomycin sulphate t%li%manage and prevent infection-related complications.

Key Market Challenges

Adverse Side Effects

A major challenge in the global neomycin sulphate market is the potential for severe side effects associated with its prolonged or high-dose use. While effective, the antibiotic can cause nephrotoxicity and ototoxicity, leading t%li%kidney damage and hearing loss. These risks have led t%li%increased caution among healthcare providers and stricter regulatory oversight. As a result, neomycin sulphate usage is often limited t%li%short-term or topical applications in human medicine. Meanwhile, the veterinary sector faces heightened scrutiny due t%li%the risk of antibiotic residues in animal-derived products, which raises public health concerns. This has led t%li%a gradual shift toward alternative antibiotics with better safety profiles.

Key Market Trends

Rising Demand of Neomycin Sulphate in Veterinary Sectors

A growing trend in the neomycin sulphate market is its increasing use in veterinary medicine. Chickens dominate global poultry production, comprising over 90% of the sector, followed by ducks, turkeys, guineafowl, and geese. As global demand for animal protein rises, s%li%does the need for effective veterinary antibiotics. Neomycin sulphate is widely used t%li%treat gastrointestinal and topical bacterial infections in livestock and poultry due t%li%its proven efficacy against gram-negative bacteria. This trend is particularly pronounced in regions with large-scale animal farming operations, where maintaining animal health is essential for productivity and food safety.

Key Market Players

• Pfizer Limited
• Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• Myland Pharma Pvt Ltd
• Xi'an International Healthcare Factory Co., Ltd.
• Shandong Yifan Chemical Technology Co., Ltd.
• Xi'an Henrikang Biotech Co., Ltd.
• Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• Jinya%li%Xinrui Pharmaceutical
• Xinyu Pharmaceutical
• Renfu Pharmaceutical

Report Scope:

In this report, the Global Neomycin Sulphate Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:

• Neomycin Sulphate Market, By Sales Channel:
• Direct
• Indirect
• Neomycin Sulphate Market, By End Use:
• Skin Infection
• Eye Infection
• Ear Infection
• Vaccine Production
• Veterinary Medicine
• Others
• Neomycin Sulphate Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neomycin Sulphate Market.

Available Customizations:

Global Neomycin Sulphate Market report with the given market data, TechSci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up t%li%five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. IMPACT OF COVID-19 ON GLOBAL NEOMYCIN SULPHATE MARKET

5. GLOBAL NEOMYCIN SULPHATE MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Sales Channel (Direct, Indirect)
  5.2.2. By End Use (Skin Infection, Eye Infection, Ear Infection, Vaccine Production, Veterinary Medicine, Others)
  5.2.3. By Region
  5.2.4. By Company (2024)
5.3. Market Map

6. NORTH AMERICA NEOMYCIN SULPHATE MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Sales Channel
  6.2.2. By End Use
  6.2.3. By Country
6.3. North America: Country Analysis
  6.3.1. United States Neomycin Sulphate Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Sales Channel
      6.3.1.2.2. By End Use
  6.3.2. Mexico Neomycin Sulphate Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Sales Channel
      6.3.2.2.2. By End Use
  6.3.3. Canada Neomycin Sulphate Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Sales Channel
      6.3.3.2.2. By End Use

7. EUROPE NEOMYCIN SULPHATE MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Sales Channel
  7.2.2. By End Use
  7.2.3. By Country
7.3. Europe: Country Analysis
  7.3.1. France Neomycin Sulphate Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Sales Channel
      7.3.1.2.2. By End Use
  7.3.2. Germany Neomycin Sulphate Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Sales Channel
      7.3.2.2.2. By End Use
  7.3.3. United Kingdom Neomycin Sulphate Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Sales Channel
      7.3.3.2.2. By End Use
  7.3.4. Italy Neomycin Sulphate Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Sales Channel
      7.3.4.2.2. By End Use
  7.3.5. Spain Neomycin Sulphate Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Sales Channel
      7.3.5.2.2. By End Use

8. ASIA PACIFIC NEOMYCIN SULPHATE MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Sales Channel
  8.2.2. By End Use
  8.2.3. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Neomycin Sulphate Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Sales Channel
      8.3.1.2.2. By End Use
  8.3.2. India Neomycin Sulphate Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Sales Channel
      8.3.2.2.2. By End Use
  8.3.3. South Korea Neomycin Sulphate Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Sales Channel
      8.3.3.2.2. By End Use
  8.3.4. Japan Neomycin Sulphate Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Sales Channel
      8.3.4.2.2. By End Use
  8.3.5. Australia Neomycin Sulphate Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Sales Channel
      8.3.5.2.2. By End Use

9. SOUTH AMERICA NEOMYCIN SULPHATE MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Sales Channel
  9.2.2. By End Use
  9.2.3. By Country
9.3. South America: Country Analysis
  9.3.1. Brazil Neomycin Sulphate Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Sales Channel
      9.3.1.2.2. By End Use
  9.3.2. Argentina Neomycin Sulphate Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Sales Channel
      9.3.2.2.2. By End Use
  9.3.3. Colombia Neomycin Sulphate Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Sales Channel
      9.3.3.2.2. By End Use

10. MIDDLE EAST AND AFRICA NEOMYCIN SULPHATE MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Sales Channel
  10.2.2. By End Use
  10.2.3. By Country
10.3. MEA: Country Analysis
  10.3.1. South Africa Neomycin Sulphate Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Sales Channel
      10.3.1.2.2. By End Use
  10.3.2. Saudi Arabia Neomycin Sulphate Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Sales Channel
      10.3.2.2.2. By End Use
  10.3.3. UAE Neomycin Sulphate Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Sales Channel
      10.3.3.2.2. By End Use

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL NEOMYCIN SULPHATE MARKET: SWOT ANALYSIS

14. PORTERS FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Pfizer Limited
  15.1.1. Business Overview
  15.1.2. Company Snapshot
  15.1.3. Products & Services
  15.1.4. Financials (As Reported)
  15.1.5. Recent Developments
  15.1.6. Key Personnel Details
  15.1.7. SWOT Analysis
15.2. Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
15.3. Myland Pharma Pvt Ltd
15.4. Xi'an International Healthcare Factory Co., Ltd.
15.5. Shandong Yifan Chemical Technology Co., Ltd.
15.6. Xi'an Henrikang Biotech Co., Ltd.
15.7. Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
15.8. Jinyao Xinrui Pharmaceutical
15.9. Xinyu Pharmaceutical
15.10. Renfu Pharmaceutical

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER